RyboDyn, Inc. is targeting the dark proteome to make new immunotherapies. We are unlocking and validating previously undiscovered, disease-specific targets that will impact the treatment of cancer and autoimmune diseases by driving a new wave of targeted therapeutics. Our "targets-to-assets" therapeutics development program is supported by a scalable, in-house platform for lead discovery and optimization. We aim to deliver first-in-class assets that recognize these targets for treating solid tumors and diseases lacking effective treatment options.